Sign In
Buy CDNA
$22.31
+0.240 (+1.09%)
At Close: Jun 03, 2026
CareDx: Shaking Off First-Mover Disadvantage
12:41pm, Tuesday, 18'th Oct 2022
The introduction of new products and the further extension of reimbursement routes are projected to fuel CDNA growth. CDNA is renewing its emphasis on profitability after a widening loss caused a 14%
5 Top Stocks Cathie Wood Is Buying This Week
04:44pm, Friday, 30'th Sep 2022
Last week, Cathie Wood made headlines after it was announced that she would relinquish her position as portfolio manager over two of her exchange-traded funds (ETFs), the 3D Printing ETF (BATS: PRNT )
Cathie Wood's Ark Invest Adds $7M Of Bitcoin-Focused Block Shares, Also Picks Up Some CareDx Stock
09:12pm, Wednesday, 14'th Sep 2022
Cathie Wood-led Ark Investment Management has bought over 100,000 shares of Jack Dorsey's Block Inc (NYSE: SQ), valued at over $6.9 million based on Wednesday's closing price.
CareDx (CDNA) – Cathie Wood's Ark Invest Adds $3M In CareDx Shares Despite Bleak Q2 Results
06:12am, Tuesday, 30'th Aug 2022
Cathie Wood-led Ark Investment Management loaded up on 153,917 shares of precision medicine company CareDx Inc (NASDAQ: CDNA), via the ARK Genomic Revolution ETF (NYSE: ARKG
Coinbase To $115? Plus This Analyst Cuts PT On Syros Pharmaceuticals By 67%
12:41pm, Wednesday, 10'th Aug 2022 Benzinga
Deutsche Bank boosted the price target on FactSet Research Systems Inc. (NYSE: FDS) from $418 to $463. However, Deutsche Bank analyst Faiza Alwy maintained the stock with a Hold rating. FactSet Resea
CareDx: Best Near Cap-Gain Health Diagnostics Prospect Say Market Makers
08:04am, Monday, 08'th Aug 2022
Which of the healthcare diagnostic services producers is now a better buy to help build your portfolio's near-term capital value? Near-term only, repetition provides long term. Find out here what the
CareDx, Inc. (CDNA) CEO Reg Seeto on Q2 2022 Results - Earnings Call Transcript
11:34am, Sunday, 07'th Aug 2022
CareDx, Inc. (NASDAQ:CDNA ) Q2 2022 Results Conference Call August 4, 2022 4:30 PM ET Company Participants Ian Cooney - VP, IR Reg Seeto - CEO Abhishek Jain - Interim CFO Conference Call Participants
CareDx (CDNA) Reports Q2 Loss, Lags Revenue Estimates
09:45pm, Thursday, 04'th Aug 2022 Zacks Investment Research
CareDx (CDNA) delivered earnings and revenue surprises of -62.50% and 3.05%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
CareDx Receives CE Mark for AlloSeq HCT for Use in Hematopoietic Cell Transplantation
10:00am, Tuesday, 24'th May 2022 GlobeNewswire Inc.
CareDx Expands Transplant Portfolio in Europe CareDx Expands Transplant Portfolio in Europe
CareDx Sponsored ISHLT Innovation Challenge Award Tackles Chronic Lung Allograft Dysfunction
11:00am, Wednesday, 18'th May 2022 GlobeNewswire Inc.
Donor-Derived Cell-Free DNA will be Used to Evaluate Treatment to Improve Lung Transplant Outcomes Donor-Derived Cell-Free DNA will be Used to Evaluate Treatment to Improve Lung Transplant Outcomes
CareDx, Inc (CDNA) CEO Reg Seeto on Q1 2022 Results - Earnings Call Transcript
10:50pm, Thursday, 05'th May 2022
CareDx, Inc (NASDAQ:CDNA ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Ian Cooney - VP of IR Reg Seeto - CEO Ankur Dhingra - CFO Conference Call Participants Alex Nowa
CareDx (CDNA) Reports Q1 Loss, Tops Revenue Estimates
09:35pm, Thursday, 05'th May 2022 Zacks Investment Research
CareDx (CDNA) delivered earnings and revenue surprises of -225% and 1%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
CareDx (CDNA) Reports Q1 Loss, Tops Revenue Estimates
06:48pm, Thursday, 05'th May 2022
CareDx (CDNA) delivered earnings and revenue surprises of -225% and 1%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
These Charts Explain Why I'm Holding This Healthcare Company
11:05am, Friday, 29'th Apr 2022 The Motley Fool
Transplants are in high demand; this company is making the process of getting one smoother.
These Charts Explain Why I'm Holding This Healthcare Company
07:05am, Friday, 29'th Apr 2022
Transplants are in high demand; this company is making the process of getting one smoother.
